KRAS and pancreatic neoplasm: The Cancer Genome Atlas Research Network reported that the KRASWT tumors had significantly elevated tuberous sclerosis complex/mammalian target of rapamycin (TSC/mTOR) signaling pathway activity compared with KRAS mutant tumors, indicating that functional activation of the mTOR signaling pathway may be an alternative oncogenic driver in KRASWT pancreatic cancer (15).